Redeye saw a sales development that was lower than expected.
Fastighetsbolaget Trianon har satt upp som mål att fastighetsvärdet ska uppgå till 20 miljarder kron...
Redeye updates its estimates after reviewing Fable Media Group’s Q3 report, which showed somewhat so...
Redeye provides an update on Thunderful Group following its Q3 2024 report, which was weaker than ex...
Redeye updates its estimates following Surgical Science’s Q3 2024 report, which beat our expectation...
Ferronordic reported an overall encouraging set of Q3 2024 numbers.
Redeye is encouraged by today’s news that the CHMP, EMA's Committee for Medicinal Products for Huma...
Comment re-published: we have corrected a factual error.
- Expect weak Q3, revenue recognition from one project - Raise '24e EBIT by SEK 376m & '25e-'26e by ...
CirChem har publicerat bolagets delårsrapport för det tredje kvartalet 2024.
Alzecures forskare visar upp en stadig ström av nya resultat som stärker bolagets projekt.
Även om Cell Impacts utveckling går långsammare än vi tidigare prognostiserat bedömer vi att affärsi...
Redeye has an overall positive impression from the visit to the Hudiksvall factory.
Redeye provides a research update following the Q3 report published by Cinclus earlier today.
Redeye provides a research update following the Q3 report published by Alzinova earlier today.
We lift '24e EBITDA by 27%, '25-'26e up 9-4% Doro now closer to a done deal, could lift '28e EBITA ~...
Redeye comments on Nekkar’s Q3 report that missed our expectations, mainly driven by a lower sales a...
Redeye provides its initial take on Navigo’s Q3 2024 report, which came in considerably below our es...
Redeye notes that Q3 came in softer than anticipated, primarily due to weaker-than-expected sales in...
Redeye is again positively surprised to see CTEK beating our estimates on the top line and profitabi...
